Aussedat, Guillaume, Maucort-Boulch, Delphine, Rey, Philippe, Safar, Violaine, Karlin, Lionel, Elsensohn, Mad Helenie, Bachy, Emmanuel, Lebras, Laure, Favier, Bertrand, Vantard, Nicolas, Ghergus, Dana, Golfier, Camille, Sesques, Pierre, Lazareth, Anne, Lequeu, Hélène, Ferrant, Emmanuelle, Salles, Gilles, Nicolas-Virelizier, Emmanuelle, and Ghesquieres, Hervé
We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m2) in combination with etoposide (300 mg/m2) and ifosfamide (1500 mg/m2) at 2, 3, or 4-week intervals. Median age was 79 years (range, 64–92). The median number of previous line was 1 (range 1–8). Patients received a median of six cycles (1–12). Fourteen patients (19%) presented partial and 14 complete responses (19%). Among the 369 cycles, nine patients developed febrile neutropenia (13%), 14 a grade 3–4 neutropenia (19%), 7 a grade 3–4 thrombocytopenia (10%) without grade 3–4 non-hematological toxicity. With a median follow up of 7.8 months, the median progression-free survival, overall survival, and duration of response were 4.4 months, 9.4 months, and 12 months, respectively. This regimen represents a therapeutic option in R/R DLBCL patients ineligible to ASCT. [ABSTRACT FROM AUTHOR]